{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:29:10Z","timestamp":1791084550642,"version":"4.1.0"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01724-w","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T06:38:10Z","timestamp":1748587090000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Aptamer-based approaches in leukemia: a paradigm shift in targeted therapy"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2547-3512","authenticated-orcid":false,"given":"Alireza","family":"Bayani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munthar Kadhim","family":"Abosaoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasur","family":"Rizaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0381-9064","authenticated-orcid":false,"given":"Mobina","family":"Nazari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3285-0784","authenticated-orcid":false,"given":"Zahra","family":"Jafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1045-7613","authenticated-orcid":false,"given":"Hamed","family":"Soleimani Samarkhazan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"1724_CR1","doi-asserted-by":"crossref","first-page":"1195194","DOI":"10.3389\/fimmu.2023.1195194","volume":"14","author":"Y Lang","year":"2023","unstructured":"Lang Y, et al. Progress in construction of mouse models to investigate the pathogenesis and immune therapy of human hematological malignancy. Front Immunol. 2023;14:1195194.","journal-title":"Front Immunol"},{"issue":"1","key":"1724_CR2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10238-025-01588-0","volume":"25","author":"A Raoufi","year":"2025","unstructured":"Raoufi A, et al. Macrophages in graft-versus-host disease (GVHD): dual roles as therapeutic tools and targets. Clin Exp Med. 2025;25(1):73.","journal-title":"Clin Exp Med"},{"issue":"13","key":"1724_CR3","volume":"10","author":"Z Liu","year":"2023","unstructured":"Liu Z, et al. Immunogenic Cell Death in Hematological Malignancy Therapy. Adv Sci (Weinh). 2023;10(13): e2207475.","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"1724_CR4","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1186\/s40001-024-02108-8","volume":"29","author":"MS Hosseini","year":"2024","unstructured":"Hosseini MS, et al. Histone deacetylase inhibitors for leukemia treatment: current status and future directions. Eur J Med Res. 2024;29(1):514.","journal-title":"Eur J Med Res"},{"issue":"1","key":"1724_CR5","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40364-025-00738-6","volume":"13","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H, et al. Unveiling the potential of CLL-1: a promising target for AML therapy. Biomark Res. 2025;13(1):28.","journal-title":"Biomark Res"},{"issue":"6","key":"1724_CR6","doi-asserted-by":"crossref","first-page":"a034819","DOI":"10.1101\/cshperspect.a034819","volume":"10","author":"JAB Bispo","year":"2020","unstructured":"Bispo JAB, Pinheiro PS, Kobetz EK. Epidemiology and Etiology of Leukemia and Lymphoma. Cold Spring Harb Perspect Med. 2020;10(6):a034819.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"1724_CR7","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40164-024-00479-6","volume":"13","author":"J Liu","year":"2024","unstructured":"Liu J, et al. Decoding leukemia at the single-cell level: clonal architecture, classification, microenvironment, and drug resistance. Exp Hematol Oncol. 2024;13(1):12.","journal-title":"Exp Hematol Oncol"},{"issue":"19","key":"1724_CR8","doi-asserted-by":"crossref","first-page":"14470","DOI":"10.3390\/ijms241914470","volume":"24","author":"GR Fajardo-Ordu\u00f1a","year":"2023","unstructured":"Fajardo-Ordu\u00f1a GR, et al. Role of SIRT1 in Chemoresistant Leukemia. Int J Mol Sci. 2023;24(19):14470.","journal-title":"Int J Mol Sci"},{"key":"1724_CR9","doi-asserted-by":"publisher","DOI":"10.1080\/08982104.2025.2495261","author":"A Kubaev","year":"2025","unstructured":"Kubaev A, et al. Platelet-derived extracellular vesicles: emerging players in hemostasis and thrombosis. J Liposome Res. 2025. https:\/\/doi.org\/10.1080\/08982104.2025.2495261.","journal-title":"J Liposome Res"},{"issue":"24","key":"1724_CR10","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.3390\/cancers16244181","volume":"16","author":"J Jureczek","year":"2024","unstructured":"Jureczek J, Ka\u0142wak K, Dzi\u0119giel P. Antibody-based immunotherapies for the treatment of hematologic malignancies. Cancers (Basel). 2024;16(24):4181.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1724_CR11","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s11033-024-10200-9","volume":"52","author":"L Rajabi","year":"2025","unstructured":"Rajabi L, et al. Aqueous and ethanolic extracts of Moringa oleifera leaves induce selective cytotoxicity in Raji and Jurkat cell lines by activating the P21 pathway independent of P53. Mol Biol Rep. 2025;52(1):102.","journal-title":"Mol Biol Rep"},{"key":"1724_CR12","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1039\/D0BM00129E","volume":"8","author":"L Huang","year":"2020","unstructured":"Huang L, et al. Nanomedicine - a promising therapy for hematological malignancies. Biomater Sci. 2020;8:2376.","journal-title":"Biomater Sci"},{"key":"1724_CR13","unstructured":"Noroozi Aghide AH, Soleimani S, Ahmadnezhad M (2016) Effect of Harmine Alkaloid on the Expression of P16 and DAPK in HL60 Leukemia Cell Line. ajaums-jps, 11(3): 28"},{"issue":"22","key":"1724_CR14","doi-asserted-by":"crossref","first-page":"8655","DOI":"10.3390\/ijms21228655","volume":"21","author":"WY Lin","year":"2020","unstructured":"Lin WY, et al. Gene modified CAR-T cellular therapy for hematologic malignancies. Int J Mol Sci. 2020;21(22):8655.","journal-title":"Int J Mol Sci"},{"key":"1724_CR15","doi-asserted-by":"crossref","first-page":"107602962513394","DOI":"10.1177\/10760296251339421","volume":"31","author":"A Hussein","year":"2025","unstructured":"Hussein A, et al. Unraveling the clot-miscarriage nexus: mechanisms, management, and future directions in thrombosis-related recurrent pregnancy loss. Clin Appl Thromb Hemost. 2025;31:10760296251339420.","journal-title":"Clin Appl Thromb Hemost"},{"key":"1724_CR16","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110902","volume":"132","author":"Y Ning","year":"2020","unstructured":"Ning Y, Hu J, Lu F. Aptamers used for biosensors and targeted therapy. Biomed Pharmacother. 2020;132: 110902.","journal-title":"Biomed Pharmacother"},{"key":"1724_CR17","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.critrevonc.2016.08.003","volume":"106","author":"W Ouyang","year":"2016","unstructured":"Ouyang W, et al. Aptamers in hematological malignancies and their potential therapeutic implications. Crit Rev Oncol Hematol. 2016;106:108\u201317.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"1724_CR18","doi-asserted-by":"crossref","first-page":"23","DOI":"10.7150\/thno.10202","volume":"5","author":"D Xiang","year":"2015","unstructured":"Xiang D, et al. Nucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicine. Theranostics. 2015;5(1):23\u201342.","journal-title":"Theranostics"},{"issue":"4","key":"1724_CR19","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.apsb.2023.01.017","volume":"13","author":"J He","year":"2023","unstructured":"He J, et al. Recent progress of aptamer-drug conjugates in cancer therapy. Acta Pharm Sin B. 2023;13(4):1358\u201370.","journal-title":"Acta Pharm Sin B"},{"key":"1724_CR20","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.omtn.2018.08.023","volume":"13","author":"S Yang","year":"2018","unstructured":"Yang S, et al. Oligonucleotide aptamer-mediated precision therapy of hematological malignancies. Mol Ther Nucleic Acids. 2018;13:164\u201375.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"9","key":"1724_CR21","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.3390\/ijms21093252","volume":"21","author":"V Giudice","year":"2020","unstructured":"Giudice V, et al. Aptamers and antisense oligonucleotides for diagnosis and treatment of hematological diseases. Int J Mol Sci. 2020;21(9):3252.","journal-title":"Int J Mol Sci"},{"issue":"23","key":"1724_CR22","doi-asserted-by":"crossref","first-page":"6902","DOI":"10.7150\/jca.49532","volume":"11","author":"J Han","year":"2020","unstructured":"Han J, et al. Application and development of aptamer in cancer: from clinical diagnosis to cancer therapy. J Cancer. 2020;11(23):6902\u201315.","journal-title":"J Cancer"},{"issue":"11","key":"1724_CR23","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3390\/bioengineering9110635","volume":"9","author":"SC Wang","year":"2022","unstructured":"Wang SC, et al. The landscape of nucleic-acid-based aptamers for treatment of hematologic malignancies: challenges and future directions. Bioengineering (Basel). 2022;9(11):635.","journal-title":"Bioengineering (Basel)"},{"issue":"12","key":"1724_CR24","doi-asserted-by":"crossref","first-page":"13446","DOI":"10.18632\/oncotarget.7178","volume":"7","author":"G Zhou","year":"2016","unstructured":"Zhou G, et al. Aptamers: a promising chemical antibody for cancer therapy. Oncotarget. 2016;7(12):13446\u201363.","journal-title":"Oncotarget"},{"issue":"3","key":"1724_CR25","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrd.2016.199","volume":"16","author":"J Zhou","year":"2017","unstructured":"Zhou J, Rossi J. Aptamers as targeted therapeutics: current potential and challenges. Nat Rev Drug Discov. 2017;16(3):181\u2013202.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"1724_CR26","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.biotechadv.2015.02.008","volume":"33","author":"M Darmostuk","year":"2015","unstructured":"Darmostuk M, et al. Current approaches in SELEX: an update to aptamer selection technology. Biotechnol Adv. 2015;33(6):1141\u201361.","journal-title":"Biotechnol Adv"},{"issue":"Supplement 1","key":"1724_CR27","doi-asserted-by":"crossref","first-page":"5750","DOI":"10.1182\/blood-2023-187498","volume":"142","author":"A Chin","year":"2023","unstructured":"Chin A, et al. Lintuzumab-Ac225, a CD33-directed antibody radiotherapy, targets AML in a mutation agnostic manner. Blood. 2023;142(Supplement 1):5750\u20135750.","journal-title":"Blood"},{"issue":"23","key":"1724_CR28","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.3390\/molecules24234229","volume":"24","author":"T Adachi","year":"2019","unstructured":"Adachi T, Nakamura Y. Aptamers: a review of their chemical properties and modifications for therapeutic application. Molecules. 2019;24(23):4229.","journal-title":"Molecules"},{"key":"1724_CR29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmgm.2021.107872","volume":"105","author":"NA Ahmad","year":"2021","unstructured":"Ahmad NA, et al. In silico approach for Post-SELEX DNA aptamers: a mini-review. J Mol Graph Model. 2021;105: 107872.","journal-title":"J Mol Graph Model"},{"issue":"3","key":"1724_CR30","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgeb.2024.100400","volume":"22","author":"DJ Chinchilla-C\u00e1rdenas","year":"2024","unstructured":"Chinchilla-C\u00e1rdenas DJ, et al. Current developments of SELEX technologies and prospects in the aptamer selection with clinical applications. J Genet Eng Biotechnol. 2024;22(3): 100400.","journal-title":"J Genet Eng Biotechnol"},{"key":"1724_CR31","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.aca.2015.11.026","volume":"904","author":"YS Borghei","year":"2016","unstructured":"Borghei YS, et al. Visual detection of cancer cells by colorimetric aptasensor based on aggregation of gold nanoparticles induced by DNA hybridization. Anal Chim Acta. 2016;904:92\u20137.","journal-title":"Anal Chim Acta"},{"issue":"16","key":"1724_CR32","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.1007\/s00253-016-7686-2","volume":"100","author":"SC Gopinath","year":"2016","unstructured":"Gopinath SC, et al. Cell-targeting aptamers act as intracellular delivery vehicles. Appl Microbiol Biotechnol. 2016;100(16):6955\u201369.","journal-title":"Appl Microbiol Biotechnol"},{"key":"1724_CR33","doi-asserted-by":"crossref","first-page":"10597","DOI":"10.2147\/OTT.S223946","volume":"12","author":"Y Tan","year":"2019","unstructured":"Tan Y, Li Y, Tang F. Nucleic acid aptamer: a novel potential diagnostic and therapeutic tool for leukemia. Onco Targets Ther. 2019;12:10597\u2013613.","journal-title":"Onco Targets Ther"},{"key":"1724_CR34","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.talanta.2014.03.056","volume":"126","author":"W Shan","year":"2014","unstructured":"Shan W, et al. An aptamer-based quartz crystal microbalance biosensor for sensitive and selective detection of leukemia cells using silver-enhanced gold nanoparticle label. Talanta. 2014;126:130\u20135.","journal-title":"Talanta"},{"issue":"7","key":"1724_CR35","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.bios.2009.11.022","volume":"25","author":"Y Pan","year":"2010","unstructured":"Pan Y, et al. Selective collection and detection of leukemia cells on a magnet-quartz crystal microbalance system using aptamer-conjugated magnetic beads. Biosens Bioelectron. 2010;25(7):1609\u201314.","journal-title":"Biosens Bioelectron"},{"issue":"19","key":"1724_CR36","doi-asserted-by":"crossref","first-page":"9355","DOI":"10.1021\/acs.analchem.6b02864","volume":"88","author":"Z Li","year":"2016","unstructured":"Li Z, et al. DNA-programmed quantum dot polymerization for ultrasensitive molecular imaging of cancer cells. Anal Chem. 2016;88(19):9355\u20138.","journal-title":"Anal Chem"},{"issue":"8","key":"1724_CR37","doi-asserted-by":"crossref","first-page":"9500","DOI":"10.1021\/acsami.0c05750","volume":"13","author":"S Ni","year":"2021","unstructured":"Ni S, et al. Recent progress in aptamer discoveries and modifications for therapeutic applications. ACS Appl Mater Interfaces. 2021;13(8):9500\u201319.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"2","key":"1724_CR38","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s43393-022-00140-5","volume":"3","author":"R Cai","year":"2023","unstructured":"Cai R, et al. Systematic bio-fabrication of aptamers and their applications in engineering biology. Syst Microbiol Biomanuf. 2023;3(2):223\u201345.","journal-title":"Syst Microbiol Biomanuf"},{"issue":"1","key":"1724_CR39","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/s11671-016-1512-8","volume":"11","author":"J Tan","year":"2016","unstructured":"Tan J, et al. Aptamer-functionalized fluorescent silica nanoparticles for highly sensitive detection of leukemia cells. Nanoscale Res Lett. 2016;11(1):298.","journal-title":"Nanoscale Res Lett"},{"issue":"8","key":"1724_CR40","first-page":"771","volume":"37","author":"P Zhu","year":"2012","unstructured":"Zhu P, et al. In vitro selection of single strand deoxyribonucleic acid aptamers binding to cells from patients with acute myeloblastic leukemia. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2012;37(8):771\u20136.","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"issue":"4","key":"1724_CR41","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3390\/molecules23040715","volume":"23","author":"M Haghighi","year":"2018","unstructured":"Haghighi M, Khanahmad H, Palizban A. Selection and Characterization of single-stranded DNA aptamers binding human B-cell surface protein CD20 by Cell-SELEX. Molecules. 2018;23(4):715.","journal-title":"Molecules"},{"issue":"11","key":"1724_CR42","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1007\/s00216-017-0238-5","volume":"409","author":"M Leitner","year":"2017","unstructured":"Leitner M, et al. Characterization of the specific interaction between the DNA aptamer sgc8c and protein tyrosine kinase-7 receptors at the surface of T-cells by biosensing AFM. Anal Bioanal Chem. 2017;409(11):2767\u201376.","journal-title":"Anal Bioanal Chem"},{"issue":"1","key":"1724_CR43","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1177\/0885328217712111","volume":"32","author":"A Bahreyni","year":"2017","unstructured":"Bahreyni A, et al. Identification and imaging of leukemia cells using dual-aptamer-functionalized graphene oxide complex. J Biomater Appl. 2017;32(1):74\u201381.","journal-title":"J Biomater Appl"},{"issue":"11","key":"1724_CR44","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1002\/elan.200804563","volume":"21","author":"C Pan","year":"2009","unstructured":"Pan C, et al. Aptamer-Based Electrochemical Sensor for Label-Free Recognition and Detection of Cancer Cells. Electroanalysis. 2009;21(11):1321\u20136.","journal-title":"Electroanalysis"},{"issue":"1","key":"1724_CR45","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1080\/10717544.2017.1367976","volume":"24","author":"H Wu","year":"2017","unstructured":"Wu H, et al. Novel CD123-aptamer-originated targeted drug trains for selectively delivering cytotoxic agent to tumor cells in acute myeloid leukemia theranostics. Drug Deliv. 2017;24(1):1216\u201329.","journal-title":"Drug Deliv"},{"key":"1724_CR46","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1756-8722-7-5","volume":"7","author":"M Yang","year":"2014","unstructured":"Yang M, et al. Developing aptamer probes for acute myelogenous leukemia detection and surface protein biomarker discovery. J Hematol Oncol. 2014;7:5.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1724_CR47","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1089\/nat.2012.0388","volume":"23","author":"ED Pratico","year":"2013","unstructured":"Pratico ED, Sullenger BA, Nair SK. Identification and characterization of an agonistic aptamer against the T cell costimulatory receptor, OX40. Nucleic Acid Ther. 2013;23(1):35\u201343.","journal-title":"Nucleic Acid Ther"},{"issue":"5","key":"1724_CR48","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1124\/mol.109.055947","volume":"76","author":"S Soundararajan","year":"2009","unstructured":"Soundararajan S, et al. Plasma membrane nucleolin is a receptor for the anticancer aptamer aS1411 in MV4-11 leukemia cells. Mol Pharmacol. 2009;76(5):984\u201391.","journal-title":"Mol Pharmacol"},{"issue":"3","key":"1724_CR49","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/elan.201600505","volume":"29","author":"T Yu","year":"2017","unstructured":"Yu T, et al. A simple electrochemical aptamer cytosensor for direct detection of chronic myelogenous leukemia K562 cells. Electroanalysis. 2017;29(3):828\u201334.","journal-title":"Electroanalysis"},{"issue":"17","key":"1724_CR50","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e36552","volume":"10","author":"C Zong","year":"2024","unstructured":"Zong C, Ran X. High sensitive aptasensing chronic myeloid leukemia on circular electrode-modified by single-walled carbon nanotube. Heliyon. 2024;10(17): e36552.","journal-title":"Heliyon"},{"issue":"4","key":"1724_CR51","first-page":"623","volume":"12","author":"Y Nur","year":"2024","unstructured":"Nur Y, et al. Cerium oxide nanoparticles-assisted aptasensor for chronic myeloid leukaemia detection. Admet dmpk. 2024;12(4):623\u201335.","journal-title":"Admet dmpk"},{"issue":"7","key":"1724_CR52","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1182\/blood-2013-03-493924","volume":"123","author":"J Hoellenriegel","year":"2014","unstructured":"Hoellenriegel J, et al. The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization. Blood. 2014;123(7):1032\u20139.","journal-title":"Blood"},{"key":"1724_CR53","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ijbiomac.2019.04.141","volume":"133","author":"F Moccia","year":"2019","unstructured":"Moccia F, et al. The role of G-quadruplex structures of LIGS-generated aptamers R1.2 and R1.3 in IgM specific recognition. Int J Biol Macromol. 2019;133:839\u201349.","journal-title":"Int J Biol Macromol"},{"issue":"6","key":"1724_CR54","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1080\/17474086.2017.1326811","volume":"10","author":"B Tomlinson","year":"2017","unstructured":"Tomlinson B, Lazarus HM. Enhancing acute myeloid leukemia therapy - monitoring response using residual disease testing as a guide to therapeutic decision-making. Expert Rev Hematol. 2017;10(6):563\u201374.","journal-title":"Expert Rev Hematol"},{"issue":"20","key":"1724_CR55","volume":"16","author":"Y Liu","year":"2020","unstructured":"Liu Y, et al. Highly sensitive minimal residual disease detection by biomimetic multivalent aptamer nanoclimber functionalized microfluidic chip. Small. 2020;16(20): e2000949.","journal-title":"Small"},{"issue":"12","key":"1724_CR56","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1166\/jbn.2016.2302","volume":"12","author":"X Li","year":"2016","unstructured":"Li X, et al. A smart detection system based on specific magnetic and rolling cycle amplification signal-amplified dual-aptamers to accurately monitor minimal residual diseases in patients with T-ALL. J Biomed Nanotechnol. 2016;12(12):2151\u201360.","journal-title":"J Biomed Nanotechnol"},{"issue":"3","key":"1724_CR57","first-page":"561","volume":"19","author":"SQ Zhang","year":"2011","unstructured":"Zhang SQ, et al. Screening and structure analysis of nucleic acid aptamers binding to surface of CD33(+)\/CD34(+) cells from patients with acute myeloid leukemia subtype M2. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011;19(3):561\u20135.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"12","key":"1724_CR58","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.3390\/bios12121070","volume":"12","author":"J Su","year":"2022","unstructured":"Su J, et al. A Hemin-graphene nanocomposite-based aptasensor for ultrasensitive colorimetric quantification of leukaemia cells using magnetic enrichment. Biosensors (Basel). 2022;12(12):1070.","journal-title":"Biosensors (Basel)"},{"issue":"7","key":"1724_CR59","doi-asserted-by":"crossref","first-page":"646","DOI":"10.3390\/pharmaceutics12070646","volume":"12","author":"P Kumar Kulabhusan","year":"2020","unstructured":"Kumar Kulabhusan P, Hussain B, Y\u00fcce M. Current perspectives on aptamers as diagnostic tools and therapeutic agents. Pharmaceutics. 2020;12(7):646.","journal-title":"Pharmaceutics"},{"issue":"2","key":"1724_CR60","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/leu.2008.335","volume":"23","author":"K Sefah","year":"2009","unstructured":"Sefah K, et al. Molecular recognition of acute myeloid leukemia using aptamers. Leukemia. 2009;23(2):235\u201344.","journal-title":"Leukemia"},{"issue":"3","key":"1724_CR61","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1039\/C8BM01393D","volume":"7","author":"C Yang","year":"2019","unstructured":"Yang C, et al. Rapid identification of specific DNA aptamers precisely targeting CD33 positive leukemia cells through a paired cell-based approach. Biomater Sci. 2019;7(3):938\u201350.","journal-title":"Biomater Sci"},{"issue":"6","key":"1724_CR62","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/nprot.2010.66","volume":"5","author":"K Sefah","year":"2010","unstructured":"Sefah K, et al. Development of DNA aptamers using Cell-SELEX. Nat Protoc. 2010;5(6):1169\u201385.","journal-title":"Nat Protoc"},{"issue":"1","key":"1724_CR63","doi-asserted-by":"crossref","first-page":"19174","DOI":"10.1038\/s41598-021-98676-4","volume":"11","author":"KG Earnest","year":"2021","unstructured":"Earnest KG, et al. Development and characterization of a DNA aptamer for MLL-AF9 expressing acute myeloid leukemia cells using whole cell-SELEX. Sci Rep. 2021;11(1):19174.","journal-title":"Sci Rep"},{"issue":"15","key":"1724_CR64","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1046\/j.1432-1033.2003.03713.x","volume":"270","author":"B Dapas","year":"2003","unstructured":"Dapas B, et al. Identification of different isoforms of eEF1A in the nuclear fraction of human T-lymphoblastic cancer cell line specifically binding to aptameric cytotoxic GT oligomers. Eur J Biochem. 2003;270(15):3251\u201362.","journal-title":"Eur J Biochem"},{"key":"1724_CR65","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.biochi.2018.06.003","volume":"151","author":"W Zhou","year":"2018","unstructured":"Zhou W, et al. Screening and characterization of an Annexin A2 binding aptamer that inhibits the proliferation of myeloma cells. Biochimie. 2018;151:150\u20138.","journal-title":"Biochimie"},{"issue":"3","key":"1724_CR66","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0092-8674(92)90180-K","volume":"68","author":"H D\u00fcrkop","year":"1992","unstructured":"D\u00fcrkop H, et al. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin\u2019s disease. Cell. 1992;68(3):421\u20137.","journal-title":"Cell"},{"issue":"35","key":"1724_CR67","doi-asserted-by":"crossref","first-page":"8909","DOI":"10.1016\/j.biomaterials.2013.07.099","volume":"34","author":"P Parekh","year":"2013","unstructured":"Parekh P, et al. Immunotherapy of CD30-expressing lymphoma using a highly stable ssDNA aptamer. Biomaterials. 2013;34(35):8909\u201317.","journal-title":"Biomaterials"},{"issue":"1","key":"1724_CR68","volume":"52","author":"M Liu","year":"2019","unstructured":"Liu M, et al. Aptamer-targeted DNA nanostructures with doxorubicin to treat protein tyrosine kinase 7-positive tumours. Cell Prolif. 2019;52(1): e12511.","journal-title":"Cell Prolif"},{"issue":"4","key":"1724_CR69","doi-asserted-by":"crossref","first-page":"780","DOI":"10.3390\/cancers12040780","volume":"12","author":"Z Zeng","year":"2020","unstructured":"Zeng Z, Tung CH, Zu Y. Aptamer-equipped protamine nanomedicine for precision lymphoma therapy. Cancers (Basel). 2020;12(4):780.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"1724_CR70","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3109\/10611860903434050","volume":"18","author":"SM Taghdisi","year":"2010","unstructured":"Taghdisi SM, et al. Targeted delivery of daunorubicin to T-cell acute lymphoblastic leukemia by aptamer. J Drug Target. 2010;18(4):277\u201381.","journal-title":"J Drug Target"},{"key":"1724_CR71","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.biomaterials.2015.07.025","volume":"67","author":"N Zhao","year":"2015","unstructured":"Zhao N, et al. Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia. Biomaterials. 2015;67:42\u201351.","journal-title":"Biomaterials"},{"key":"1724_CR72","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1182\/blood-2019-127100","volume":"134","author":"K Tarlock","year":"2019","unstructured":"Tarlock K, et al. CD117 expression is associated with cytogenetic and molecular profiles and outcome in pediatric acute myeloid leukemia. Blood. 2019;134:2699\u20132699.","journal-title":"Blood"},{"issue":"3","key":"1724_CR73","doi-asserted-by":"crossref","first-page":"316","DOI":"10.4161\/rna.6.3.8808","volume":"6","author":"AC Yan","year":"2009","unstructured":"Yan AC, Levy M. Aptamers and aptamer targeted delivery. RNA Biol. 2009;6(3):316\u201320.","journal-title":"RNA Biol"},{"issue":"4","key":"1724_CR74","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s10637-016-0339-6","volume":"34","author":"O Kadioglu","year":"2016","unstructured":"Kadioglu O, Efferth T. Peptide aptamer identified by molecular docking targeting translationally controlled tumor protein in leukemia cells. Invest New Drugs. 2016;34(4):515\u201321.","journal-title":"Invest New Drugs"},{"issue":"4","key":"1724_CR75","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0093441","volume":"9","author":"JW Kotula","year":"2014","unstructured":"Kotula JW, et al. Targeted disruption of \u03b2-arrestin 2-mediated signaling pathways by aptamer chimeras leads to inhibition of leukemic cell growth. PLoS ONE. 2014;9(4): e93441.","journal-title":"PLoS ONE"},{"issue":"7","key":"1724_CR76","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1182\/blood-2013-12-542480","volume":"123","author":"R Marasca","year":"2014","unstructured":"Marasca R, Maffei R. NOX-A12: mobilizing CLL away from home. Blood. 2014;123(7):952\u20133.","journal-title":"Blood"},{"issue":"12","key":"1724_CR77","doi-asserted-by":"crossref","first-page":"6742","DOI":"10.3390\/ijms25126742","volume":"25","author":"G Santarpia","year":"2024","unstructured":"Santarpia G, Carnes E. Therapeutic applications of aptamers. Int J Mol Sci. 2024;25(12):6742.","journal-title":"Int J Mol Sci"},{"issue":"21","key":"1724_CR78","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1182\/blood.V124.21.1996.1996","volume":"124","author":"M Steurer","year":"2014","unstructured":"Steurer M, et al. Results from a Phase IIa Study of the Anti-CXCL12 Spiegelmer Olaptesed Pegol (NOX-A12) in Combination with bendamustine\/rituximab in patients with chronic lymphocytic leukemia. Blood. 2014;124(21):1996\u20131996.","journal-title":"Blood"},{"issue":"2","key":"1724_CR79","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1517\/17460441.2016.1126244","volume":"11","author":"GT Rozenblum","year":"2016","unstructured":"Rozenblum GT, et al. Aptamers: current challenges and future prospects. Expert Opin Drug Discov. 2016;11(2):127\u201335.","journal-title":"Expert Opin Drug Discov"},{"issue":"1","key":"1724_CR80","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3390\/cancers15010300","volume":"15","author":"Y Liao","year":"2023","unstructured":"Liao Y, et al. The research advances of aptamers in hematologic malignancies. Cancers. 2023;15(1):300.","journal-title":"Cancers"},{"issue":"6","key":"1724_CR81","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3390\/cancers9060069","volume":"9","author":"M-C Mercier","year":"2017","unstructured":"Mercier M-C, Dontenwill M, Choulier L. Selection of nucleic acid aptamers targeting tumor cell-surface protein biomarkers. Cancers. 2017;9(6):69.","journal-title":"Cancers"},{"issue":"1","key":"1724_CR82","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s00604-017-2568-6","volume":"185","author":"X Han","year":"2017","unstructured":"Han X, et al. Gold nanoparticle based photometric determination of tobramycin by using new specific DNA aptamers. Microchim Acta. 2017;185(1):4.","journal-title":"Microchim Acta"},{"issue":"5","key":"1724_CR83","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1021\/acs.analchem.1c04560","volume":"94","author":"ATH Le","year":"2022","unstructured":"Le ATH, et al. Quantitative characterization of partitioning in selection of DNA aptamers for protein targets by capillary electrophoresis. Anal Chem. 2022;94(5):2578\u201388.","journal-title":"Anal Chem"},{"issue":"1","key":"1724_CR84","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2011.08807.x","volume":"155","author":"S Shigdar","year":"2011","unstructured":"Shigdar S, et al. Clinical applications of aptamers and nucleic acid therapeutics in haematological malignancies. Br J Haematol. 2011;155(1):3\u201313.","journal-title":"Br J Haematol"},{"issue":"10","key":"1724_CR85","doi-asserted-by":"crossref","first-page":"13624","DOI":"10.3390\/s131013624","volume":"13","author":"S Shigdar","year":"2013","unstructured":"Shigdar S, et al. Aptamers as theranostic agents: modifications, serum stability and functionalisation. Sensors (Basel). 2013;13(10):13624\u201337.","journal-title":"Sensors (Basel)"},{"issue":"1","key":"1724_CR86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0033583510000181","volume":"44","author":"W Yang","year":"2011","unstructured":"Yang W. Nucleases: diversity of structure, function and mechanism. Q Rev Biophys. 2011;44(1):1\u201393.","journal-title":"Q Rev Biophys"},{"issue":"8","key":"1724_CR87","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.3390\/molecules15085423","volume":"15","author":"M Kuwahara","year":"2010","unstructured":"Kuwahara M, Sugimoto N. Molecular evolution of functional nucleic acids with chemical modifications. Molecules. 2010;15(8):5423\u201344.","journal-title":"Molecules"},{"issue":"15","key":"1724_CR88","doi-asserted-by":"crossref","first-page":"6595","DOI":"10.1021\/ac300815c","volume":"84","author":"N Derbyshire","year":"2012","unstructured":"Derbyshire N, et al. Toggled RNA aptamers against aminoglycosides allowing facile detection of antibiotics using gold nanoparticle assays. Anal Chem. 2012;84(15):6595\u2013602.","journal-title":"Anal Chem"},{"issue":"1","key":"1724_CR89","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1089\/nat.2011.0316","volume":"22","author":"FJ Hernandez","year":"2012","unstructured":"Hernandez FJ, et al. Degradation of nuclease-stabilized RNA oligonucleotides in mycoplasma-contaminated cell culture media. Nucleic Acid Ther. 2012;22(1):58\u201368.","journal-title":"Nucleic Acid Ther"},{"issue":"3","key":"1724_CR90","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0969-8051(99)00103-1","volume":"27","author":"H Dougan","year":"2000","unstructured":"Dougan H, et al. Extending the lifetime of anticoagulant oligodeoxynucleotide aptamers in blood. Nucl Med Biol. 2000;27(3):289\u201397.","journal-title":"Nucl Med Biol"},{"issue":"2","key":"1724_CR91","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.bbrc.2012.03.014","volume":"420","author":"Y Mori","year":"2012","unstructured":"Mori Y, Nakamura Y, Ohuchi S. Inhibitory RNA aptamer against SP6 RNA polymerase. Biochem Biophys Res Commun. 2012;420(2):440\u20133.","journal-title":"Biochem Biophys Res Commun"},{"issue":"51","key":"1724_CR92","doi-asserted-by":"crossref","first-page":"21530","DOI":"10.1021\/jacs.0c10902","volume":"142","author":"H Hoshino","year":"2020","unstructured":"Hoshino H, et al. DNA polymerase variants with high processivity and accuracy for encoding and decoding locked nucleic acid sequences. J Am Chem Soc. 2020;142(51):21530\u20137.","journal-title":"J Am Chem Soc"},{"key":"1724_CR93","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.omtn.2017.12.013","volume":"10","author":"W Kotkowiak","year":"2018","unstructured":"Kotkowiak W, et al. Thermodynamic, anticoagulant, and antiproliferative properties of thrombin binding aptamer containing novel UNA derivative. Mol Therap Nucleic Acids. 2018;10:304\u201316.","journal-title":"Mol Therap Nucleic Acids"},{"issue":"10","key":"1724_CR94","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/cbic.200300663","volume":"4","author":"D Eulberg","year":"2003","unstructured":"Eulberg D, Klussmann S. Spiegelmers: biostable aptamers. ChemBioChem. 2003;4(10):979\u201383.","journal-title":"ChemBioChem"},{"issue":"41","key":"1724_CR95","doi-asserted-by":"crossref","first-page":"26063","DOI":"10.1039\/C8CP04816A","volume":"20","author":"RD Teo","year":"2018","unstructured":"Teo RD, et al. Electron transfer characteristics of 2\u2032-deoxy-2\u2032-fluoro-arabinonucleic acid, a nucleic acid with enhanced chemical stability. Phys Chem Chem Phys. 2018;20(41):26063\u20137.","journal-title":"Phys Chem Chem Phys"},{"issue":"1","key":"1724_CR96","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.bbrc.2012.01.127","volume":"419","author":"C F\u00f6rster","year":"2012","unstructured":"F\u00f6rster C, et al. Properties of an \u2018LNA\u2019-modified ricin RNA aptamer. Biochem Biophys Res Commun. 2012;419(1):60\u20135.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"1724_CR97","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1089\/nat.2015.0576","volume":"26","author":"S Kakiuchi-Kiyota","year":"2016","unstructured":"Kakiuchi-Kiyota S, et al. Development of a method for profiling protein interactions with LNA-modified antisense oligonucleotides using protein microarrays. Nucleic Acid Ther. 2016;26(2):93\u2013101.","journal-title":"Nucleic Acid Ther"},{"issue":"4","key":"1724_CR98","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1089\/nat.2015.0598","volume":"26","author":"JA Engelhardt","year":"2016","unstructured":"Engelhardt JA. Comparative renal toxicopathology of antisense oligonucleotides. Nucleic Acid Ther. 2016;26(4):199\u2013209.","journal-title":"Nucleic Acid Ther"},{"issue":"8","key":"1724_CR99","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1039\/D2TB02579E","volume":"11","author":"B Jin","year":"2023","unstructured":"Jin B, et al. Aptamers in cancer therapy: problems and new breakthroughs. J Mater Chem B. 2023;11(8):1609\u201327.","journal-title":"J Mater Chem B"},{"key":"1724_CR100","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.1048148","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, et al. Strategies for developing long-lasting therapeutic nucleic acid aptamer targeting circulating protein: the present and the future. Front Cell Dev Biol. 2022. https:\/\/doi.org\/10.3389\/fcell.2022.1048148.","journal-title":"Front Cell Dev Biol"},{"issue":"10","key":"1724_CR101","volume":"4","author":"CH Lee","year":"2015","unstructured":"Lee CH, et al. Pharmacokinetics of a cholesterol-conjugated aptamer against the hepatitis C Virus (HCV) NS5B protein. Mol Ther Nucleic Acids. 2015;4(10): e254.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"13","key":"1724_CR102","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.4155\/fmc.15.94","volume":"7","author":"J Winkler","year":"2015","unstructured":"Winkler J. Therapeutic oligonucleotides with polyethylene glycol modifications. Future Med Chem. 2015;7(13):1721\u201331.","journal-title":"Future Med Chem"},{"issue":"5","key":"1724_CR103","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3390\/molecules29051124","volume":"29","author":"B Wang","year":"2024","unstructured":"Wang B, et al. Aptamer technologies in neuroscience, neuro-diagnostics and neuro-medicine development. Molecules. 2024;29(5):1124.","journal-title":"Molecules"},{"issue":"1","key":"1724_CR104","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12959-025-00727-7","volume":"23","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H, et al. Von Willebrand disease (VWD) and pregnancy: a comprehensive overview. Thromb J. 2025;23(1):41.","journal-title":"Thromb J"},{"issue":"7","key":"1724_CR105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0068810","volume":"8","author":"M Avci-Adali","year":"2013","unstructured":"Avci-Adali M, et al. Potential capacity of aptamers to trigger immune activation in human blood. PLoS ONE. 2013;8(7): e68810.","journal-title":"PLoS ONE"},{"key":"1724_CR106","unstructured":"Burdick AD et al Sequence motifs associated with hepatotoxicity of locked nucleic acid--modified antisense oligonucleotides"},{"issue":"5","key":"1724_CR107","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1093\/nar\/gky060","volume":"46","author":"W Shen","year":"2018","unstructured":"Shen W, et al. Acute hepatotoxicity of 2\u2019 fluoro-modified 5\u201310-5 gapmer phosphorothioate oligonucleotides in mice correlates with intracellular protein binding and the loss of DBHS proteins. Nucleic Acids Res. 2018;46(5):2204\u201317.","journal-title":"Nucleic Acids Res"},{"issue":"17","key":"1724_CR108","doi-asserted-by":"crossref","first-page":"5992","DOI":"10.1039\/C5AN01055A","volume":"140","author":"J Wan","year":"2015","unstructured":"Wan J, et al. Cell-SELEX based selection and optimization of DNA aptamers for specific recognition of human cholangiocarcinoma QBC-939 cells. Analyst. 2015;140(17):5992\u20137.","journal-title":"Analyst"},{"issue":"36","key":"1724_CR109","doi-asserted-by":"crossref","first-page":"20295","DOI":"10.1039\/C8RA03702G","volume":"8","author":"Q Sun","year":"2018","unstructured":"Sun Q, et al. Studies of the binding properties of the food preservative thiabendazole to DNA by computer simulations and NMR relaxation. RSC Adv. 2018;8(36):20295\u2013303.","journal-title":"RSC Adv"},{"issue":"7","key":"1724_CR110","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10822-015-9844-5","volume":"29","author":"HB Albada","year":"2015","unstructured":"Albada HB, Golub E, Willner I. Computational docking simulations of a DNA-aptamer for argininamide and related ligands. J Comput Aided Mol Des. 2015;29(7):643\u201354.","journal-title":"J Comput Aided Mol Des"},{"key":"1724_CR111","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.coche.2014.01.007","volume":"4","author":"H Xing","year":"2014","unstructured":"Xing H, et al. DNA aptamer technology for personalized medicine. Curr Opin Chem Eng. 2014;4:79\u201387.","journal-title":"Curr Opin Chem Eng"},{"issue":"1","key":"1724_CR112","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s44371-025-00094-2","volume":"2","author":"K Mpofu","year":"2025","unstructured":"Mpofu K, et al. Aptamers and antibodies in optical biosensing. Discov Chem. 2025;2(1):23.","journal-title":"Discov Chem"},{"issue":"1","key":"1724_CR113","first-page":"1","volume":"3","author":"M Farrokhi","year":"2023","unstructured":"Farrokhi M, et al. Role of precision medicine and personalized medicine in the treatment of diseases. Kindle. 2023;3(1):1\u2013164.","journal-title":"Kindle"},{"key":"1724_CR114","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ejphar.2018.07.034","volume":"834","author":"YT Lee","year":"2018","unstructured":"Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: Treating cancer with specificity. Eur J Pharmacol. 2018;834:188\u201396.","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"1724_CR115","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00432-019-02882-7","volume":"145","author":"Y Maimaitiyiming","year":"2019","unstructured":"Maimaitiyiming Y, et al. Novel insights into the role of aptamers in the fight against cancer. J Cancer Res Clin Oncol. 2019;145(4):797\u2013810.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1724_CR116","volume":"3","author":"F Pastor","year":"2016","unstructured":"Pastor F. Tumor-targeted costimulation by using bi-specific aptamers. Cancer Cell Microenviron. 2016;3: e1333.","journal-title":"Cancer Cell Microenviron"},{"issue":"7","key":"1724_CR117","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/s41375-024-02191-0","volume":"38","author":"O Kovecses","year":"2024","unstructured":"Kovecses O, Mercier FE, McKeague M. Nucleic acid therapeutics as differentiation agents for myeloid leukemias. Leukemia. 2024;38(7):1441\u201354.","journal-title":"Leukemia"},{"key":"1724_CR118","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.copbio.2019.11.008","volume":"63","author":"M Sp\u00f6ring","year":"2020","unstructured":"Sp\u00f6ring M, Finke M, Hartig JS. Aptamers in RNA-based switches of gene expression. Curr Opin Biotechnol. 2020;63:34\u201340.","journal-title":"Curr Opin Biotechnol"},{"issue":"1","key":"1724_CR119","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1080\/10717544.2021.1934191","volume":"28","author":"H Wu","year":"2021","unstructured":"Wu H, et al. Novel CD123 polyaptamer hydrogel edited by Cas9\/sgRNA for AML-targeted therapy. Drug Delivery. 2021;28(1):1166\u201378.","journal-title":"Drug Delivery"},{"issue":"3","key":"1724_CR120","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nbt.3802","volume":"35","author":"SF Dowdy","year":"2017","unstructured":"Dowdy SF. Overcoming cellular barriers for RNA therapeutics. Nat Biotechnol. 2017;35(3):222\u20139.","journal-title":"Nat Biotechnol"},{"key":"1724_CR121","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.addr.2018.07.003","volume":"134","author":"S Yoon","year":"2018","unstructured":"Yoon S, Rossi JJ. Aptamers: uptake mechanisms and intracellular applications. Adv Drug Deliv Rev. 2018;134:22\u201335.","journal-title":"Adv Drug Deliv Rev"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01724-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01724-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01724-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:46:10Z","timestamp":1764917170000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01724-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":121,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1724"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01724-w","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]},"assertion":[{"value":"18 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"186"}}